跳至主要内容
临床试验/NCT02049983
NCT02049983已完成不适用

Levita Magnetic Grasper Device Safety and Performance Study

Levita Magnetics6 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2014年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
6
主要终点
Safety Assessment of AEs

研究概览

简要总结

The purpose of this study is to determine the Levita Magnetic Grasper Device Safety and Performance in Laparoscopy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is between 18 and 60 years of age
  • Undergoing elective cholecystectomy due to:
  • Cholelithiasis (Gallbladder stones < 2.5cm in longer measurement (length or width))
  • Gallbladder polyps as assessed by ultrasound
  • Absence of non-correctable coagulopathy (INR < 1.4 or, platelet count of < 50,000/mcl)
  • Patient has a body mass index (BMI) ≤ 35 kg/m2 and over 20
  • Patient, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study mandated determinations or procedure

排除标准

  • Emergency presentation with acute gallbladder disease
  • Pancreatitis
  • Scleroatrophic gallbladder as shown by ultrasound
  • Biliary tract stones diagnosed before or during surgery
  • Acute cholecystitis
  • Gallbladder Empyema
  • Ongoing peritoneal dialysis
  • Previous abdominal surgery or laparotomy (presence of any previous upper umbilical incision)
  • Presence of umbilical hernia or previous umbilical hernia
  • American Society of Anesthesiologists (ASA) score of III or IV
  • Patient is undergoing treatment for chronic pain of any origin
  • Significant comorbidities: cardiovascular, neuromuscular, chronic obstructive pulmonary disease, and urological disease (renal failure)
  • Patients with signs of gallbladder perforation diagnosed by ultrasound
  • Suspicion of biliary cancer
  • Patients with severe peritonitis
  • Contraindications to pneumoperitoneum
  • Known allergy to paracetamol or NSAIDs
  • Patients with metallic implants (such as pacemakers, prosthesis, etc)
  • Previously diagnosed or suspected of having a history of choledocholithiasis based on any alterations in plasma hepatic enzymes
  • Has a biliary tract > 7mm in size as determined by ultrasound
  • Has a gallbladder wall thickness that is > 5mm
  • Diabetic Blood coagulation issues
  • Has signs of hepatic endocrinology (i.e: cirrhosis, liver failure, increase in liver enzymes, etc.)
  • History of endoscopic papillotomy (i.e: Preoperative indication of endoscopic retrograde cholangiopancreatography (ERCP)
  • Patient is pregnant or wishes to become pregnant during the length of study participation or lactation
  • Patient is not likely to comply with the follow-up evaluation schedule
  • Patient is participating in a clinical trial of another investigational drug or device
  • Patient is mentally incompetent or a prisoner
  • Known or suspected drug or alcohol abuse
  • Patient has systemic infection or evidence of any surgical site infection (superficial or organ space)
  • Patient has compromised immune system or autoimmune disease (WBC < 4000 or > 20,000), including prior or pending treatment for HIV or Hep. C
  • Patient intra-operatively needs an additional surgery while undergoing elective cholecystectomy

结局指标

主要结局

Safety Assessment of AEs

时间窗: During surgery

Absence of any damage or side effect to the patient directly produced by the device during the surgery

Feasibility of Mobilization

时间窗: Intra-operative

Ability to adequately mobilize the organ during the surgery

次要结局

未报告次要终点

研究者

发起方
Levita Magnetics
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Levita Magnetic Grasper Device Safety and... | 临床试验